Abbott Laboratories (ABT)

88.25
3.15 3.45
NYSE : Health Technology
Prev Close 91.40
Open 91.05
Day Low/High 88.23 / 91.33
52 Wk Low/High 61.61 / 100.00
Volume 9.07M
Avg Volume 10.62M
Exchange NYSE
Shares Outstanding 1.77B
Market Cap 163.83B
EPS 2.10
P/E Ratio 44.74
Div & Yield 1.44 (1.46%)
Pullback in Abbott Labs Gives Buyers Another Chance

Pullback in Abbott Labs Gives Buyers Another Chance

Our latest analysis and strategy on ABT shares.

Jim Cramer: Trade Wars and Tariffs May Soon Be Baked Into Pricing

Jim Cramer: Trade Wars and Tariffs May Soon Be Baked Into Pricing

Earnings have been strong, and analysts will soon start to concentrate more on actual weakness than shadow-boxing weakness.

Abbott Laboratories Gaps to the Upside in a Classic Breakout

Abbott Laboratories Gaps to the Upside in a Classic Breakout

If you are long ABT continue to hold and raise sell stop protection to a close below $59 or where the 200-day moving average line intersects.

Here Are 6 Chip Stocks That I Like Better Than Texas Instruments: Market Recon

Here Are 6 Chip Stocks That I Like Better Than Texas Instruments: Market Recon

This group is expected to post second-quarter EPS gains of 30%; here is how to trade it.

Medical Device Stocks Could Be Gearing Up to Be Market Leaders

Medical Device Stocks Could Be Gearing Up to Be Market Leaders

When chartists look for the next market leaders they often go to stocks that have held up the best during corrections.

Jim Cramer: When Rates Decline, 96% of the S&P 500 Benefits

Jim Cramer: When Rates Decline, 96% of the S&P 500 Benefits

When rates decline, most of the S&P 500 benefits, according to TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer.

Jim Cramer: Stocks That Do Well In a Declining Rate Environment Are Back

Jim Cramer: Stocks That Do Well In a Declining Rate Environment Are Back

The crash of oil will only accelerate the move.

Why I'm Not Piling 'All In' to the Banks: Market Recon

Why I'm Not Piling 'All In' to the Banks: Market Recon

Market reactions have ranged anywhere from lackluster to outright negative. What gives?

Jim Cramer: We've Got a Battle Ahead of Us, But the Fed Might Resolve It

Jim Cramer: We've Got a Battle Ahead of Us, But the Fed Might Resolve It

Sectors are saying different things about rates, but new Fed chief Jerome Powell could provide clarity at his first press conference on Wednesday.

Should You Stay Away From Healthcare Stocks?

Should You Stay Away From Healthcare Stocks?

TheStreet's founder Jim Cramer and a panel of top experts discuss how investors should be positioning their portfolio for March in this month's Trading Strategies session. In this clip above, listen to them discuss healthcare stocks and why they think they're too hard to trade.

Stay Long Abbott Labs' Investors

Stay Long Abbott Labs' Investors

ABT has been in a strong and durable uptrend and that is likely to continue.

Cramer: 10 Points to Consider

Cramer: 10 Points to Consider

Don't worry about missing anything, we haven't solved the bond conundrum and the evidence says we get to 3% with selloffs on the way.

There Is Good and a Lot of Bad in General Electric Earnings

There Is Good and a Lot of Bad in General Electric Earnings

John Flannery sees progress being made on GE's initiatives, but that is what I expected him to say.

Jim Cramer: The 3 Best Sectors That Lifted the Stock Market

Jim Cramer: The 3 Best Sectors That Lifted the Stock Market

It's hard to understand the magnitude of the change.

Cramer: How to Find the Open Receiver in a Pullback

Cramer: How to Find the Open Receiver in a Pullback

You've got to run the stock checkdown.

My Rx: Keep Holding Abbott Labs Longs

My Rx: Keep Holding Abbott Labs Longs

The drugmaker is in an uptrend with a price target of $60.

Cramer: What's Tax Reform Got to Do With It?

Cramer: What's Tax Reform Got to Do With It?

Treasury secretary says it's baked into the market, but is anyone really counting on it?

Jim Cramer on Tax Reform, Kellogg, Hain Celestial, Facebook and Western Digital

Jim Cramer on Tax Reform, Kellogg, Hain Celestial, Facebook and Western Digital

Jim Cramer weighs in on the trending news of the day from the floor of the New York Stock Exchange.

Jim Cramer: We Remain Excited About Abbott Laboratories for Action Alerts Plus

Jim Cramer: We Remain Excited About Abbott Laboratories for Action Alerts Plus

Jim Cramer explains why his Action Alerts Plus charitable portfolio is hanging on to Abbott Laboratories.

Abbott Laboratories Is Still Rising

Abbott Laboratories Is Still Rising

Stay long, and consider raising sell-stop protection to a close below $50.

The Best Companies for Women

The Best Companies for Women

Working Mother and the National Association of Female Executives surveyed companies and found the best ones that do right by women. Find out who you should be working for.

How EY's Kerrie MacPherson Uses Decades of Experience to Help a New Generation of Women Win

How EY's Kerrie MacPherson Uses Decades of Experience to Help a New Generation of Women Win

EY's Kerrie MacPherson Wants To Pave the Way for future female entrepreneurs.

Cramer: Rotations Hit Companies That Don't Deserve It

Cramer: Rotations Hit Companies That Don't Deserve It

Case in point: Home Depot and Lowe's.

Abbott Laboratories Is Set for Another Breakout

Abbott Laboratories Is Set for Another Breakout

Look to buy at the current market level.

Cramer: You Can't Bet Against the Bonds

Cramer: You Can't Bet Against the Bonds

A rotation that started as the minor chord of the rotational symphony and is now the major one.

Abbott Laboratories Saw a Recent Breakout

Abbott Laboratories Saw a Recent Breakout

Barring a close below $46, we are likely to see ABT remain firm and work higher.

Cramer: You Need 2 Monday Morning Game Plans

Cramer: You Need 2 Monday Morning Game Plans

We really want to shake out the weak hands here.

With Mother's Day Coming Up: Who Are the Best Employers for Working Moms?

With Mother's Day Coming Up: Who Are the Best Employers for Working Moms?

Female representation among the top 10% of earners at the NAFE top companies increased 2% to 41%, the highest since 2013.